Eli Lilly announced encouraging results from its latest study of its Alzheimer’s drug candidate, donanemab. In the Phase 3 study, people receiving donanemab experienced 35% slower cognitive decline than people receiving placebo
, Eli Lilly announced encouraging results from its latest study of its Alzheimer’s drug candidate, donanemab.
In the Phase 3 study, which included more than 1,000 people with early signs of Alzheimer’s disease, people receiving donanemab experienced 35% slower cognitive decline, as measured on cognitive tests, than people receiving placebo. In addition, those getting the drug showed 40% less decline in the ability to perform daily activities such as driving, managing their finances, and holding conversations.
The results are the most encouraging yet for any drug that targets amyloid, the protein that builds up in the brains of Alzheimer’s patients and leads to a gradual culling of nerves involved in memory and other cognitive skills. “This further underscores the inflection point we are at for the Alzheimer’s field,” said Maria Carrillo, chief science officer for the Alzheimer’s Association, in a statement.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Ship that toppled over in Edinburgh dry dock injuring 35 people finally righted weeks laterThirty five people were hurt when a US Navy vessel which tipped over in a dry dock. Now more than a month later, the 3,371-tonne vessel has been righted and is now afloat
Læs mere »
New Alzheimer's treatment slows decline by 35% as experts hail 'beginning of end' for disease💬 “Hugely significant moment for dementia research' The world is “on the cusp” of the first generation of treatments for Alzheimer’s disease after a new drug was found to slow decline in the brain’s capabilities, experts said
Læs mere »
Scots gran stunned after partner proposes - 35 years after ruling out a weddingGraham Martin had a sudden change of heart and popped the question on the beach at Lossiemouth.
Læs mere »
Police arrest fake ‘Boris Johnson’ after suspected drink-drive smash in NetherlandsPolice found a driver’s licence that claimed its owner was Boris Johnson - after a 35-year-old man was arrested over a suspected drink-drive crash in the Netherlands.
Læs mere »
Anti-Alzheimers molecular mechanism of icariin: insights from gut microbiota, metabolomics, and network pharmacology - Journal of Translational MedicineBackground Icariin (ICA), an active ingredient extracted from Epimedium species, has shown promising results in the treatment of Alzheimer's disease (AD), although its potential therapeutic mechanism remains largely unknown. This study aimed to investigate the therapeutic effects and the underlying mechanisms of ICA on AD by an integrated analysis of gut microbiota, metabolomics, and network pharmacology (NP). Methods The cognitive impairment of mice was measured using the Morris Water Maze test and the pathological changes were assessed using hematoxylin and eosin staining. 16S rRNA sequencing and multi-metabolomics were performed to analyze the alterations in the gut microbiota and fecal/serum metabolism. Meanwhile, NP was used to determine the putative molecular regulation mechanism of ICA in AD treatment. Results Our results revealed that ICA intervention significantly improved cognitive dysfunction in APP/PS1 mice and typical AD pathologies in the hippocampus of the APP/PS1 mice. Moreover, the gut microbiota analysis showed that ICA administration reversed AD-induced gut microbiota dysbiosis in APP/PS1 mice by elevating the abundance of Akkermansia and reducing the abundance of Alistipe. Furthermore, the metabolomic analysis revealed that ICA reversed the AD-induced metabolic disorder via regulating the glycerophospholipid and sphingolipid metabolism, and correlation analysis revealed that glycerophospholipid and sphingolipid were closely related to Alistipe and Akkermansia. Moreover, NP indicated that ICA might regulate the sphingolipid signaling pathway via the PRKCA/TNF/TP53/AKT1/RELA/NFKB1 axis for the treatment of AD. Conclusion These findings indicated that ICA may serve as a promising therapeutic approach for AD and that the ICA-mediated protective effects were associated with the amelioration of microbiota disturbance and metabolic disorder. Graphical Abstract
Læs mere »